Sun Pharma Showcases Positive Data on Dermatological Treatments at EADV Congress

Sun Pharmaceutical Industries Limited (Sun Pharma) is making waves at the 33rd European Academy of Dermatology and Venereology (EADV) Congress held in Amsterdam, Netherlands. The company announced the presentation of abstracts highlighting the effectiveness and safety of its dermatology portfolio, specifically focusing on LEQSELVI™ and ILUMYA®.

LEQSELVI™, an oral JAK inhibitor, has garnered significant attention for its promising results in treating severe alopecia areata (AA). Three abstracts were accepted for presentation, including a podium presentation showcasing impressive data on hair satisfaction. This study (FC04.04) found that a remarkable 95% of patients taking LEQSELVI™ twice daily experienced an improvement in their hair satisfaction scores over 24 weeks compared to baseline. This improvement in hair regrowth is crucial for AA patients, as the visible nature of the disease can lead to depression and anxiety. Sun Pharma will also share additional poster presentations on LEQSELVI™ (P2022 and P2081) exploring its impact on anxiety and depression in AA patients, along with dose optimisation strategies.

Sun Pharma’s focus extends beyond LEQSELVI™. Twelve poster presentations will delve into the clinical efficacy and safety of ILUMYA®, a treatment for moderate-to-severe plaque psoriasis. This data encompasses both controlled studies and real-world settings, providing a comprehensive picture of ILUMYA®’s effectiveness.

Sun Pharma’s presence at the EADV Congress underscores its commitment to developing and delivering innovative solutions for dermatological conditions that can significantly impact patients’ lives.

“Deuruxolitinib targets the immune mechanisms behind alopecia areata, providing patients with an effective treatment option,” said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair, Clinical Trials and Innovation and Director, Inpatient Dermatology, Brigham and Women’s Hospital. “As a dermatologist, I find these data particularly encouraging because it addresses the physical effects of hair loss, which can, in turn, address the significant emotional and mental health challenges that patients often face.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.